Description:FORM 2
THE PATENTS ACT, 1970
(39 of 1970)
&
THE PATENTS RULES, 2003
COMPLETE SPECIFICATION
(Section 10 and Rule 13)

1. TITLE OF THE INVENTION:
IMPLANTABLE STENT

2. APPLICANT:
Meril Life Sciences Pvt Ltd., an Indian company of the Survey No. 135/139 Bilakhia House, Muktanand Marg, Chala, Vapi-Gujarat 396191, India.

The following specification particularly describes the invention and the manner in which it is to be performed:

FIELD OF INVENTION
[001] The present disclosure relates to a medical device. More particularly, the present disclosure relates to an implantable stent.
BACKGROUND OF INVENTION
[002] Peripheral arteries, including the superficial femoral artery (SFA) and popliteal artery (shown in Fig. 1a), are components of the human circulatory system, facilitating flow of blood to the lower extremities. The SFA originates from the femoral artery and courses through the thigh, supplying oxygenated blood to the leg. The popliteal artery extends behind the knee, branching into smaller vessels to nourish the calf and foot blood vessels.
[003] These arteries are susceptible to diseases like stenosis and occlusions. Stenosis involves the narrowing of the artery, restricting blood flow. Occlusions occur when arteries are completely blocked, leading to severe consequences like ischemia or tissue damage. Endoscopy is a widely used approach for the treatment of stenosis and occlusions. Endoscopic treatment is performed by implantation of a stent.
[004] Conventionally available stents pose many challenges such as stent jumping and migration, as the stent may shift from its intended position due to designs of the stent. Extended stent lengths may also cause fractures in stent, especially in the case of lower-body applications like the leg and thigh regions, due to strong mechanical strain.
[005] Additionally, in several medical conditions, stenosis or occlusions spread through a particular length at multiple spots (for example, spots 10, 12, 14, 16 depicted in Fig. 1b) in a discontinuous manner. Such conditions require a long stent for treatment. However, the long stent poses challenges such as one or more stent fractures and/or unnecessary stenting at the healthy portions of artery. These challenges underscore the need for advancements in stent design and minimize the quantity of stent material in a human vessel.
[006] Thus, there arises a need for a stent that overcomes the problems associated with the conventional stents.
SUMMARY OF INVENTION
[007] Particular embodiments of the present disclosure are described herein below with reference to the accompanying drawings; however, it is to be understood that the disclosed embodiments are mere examples of the disclosure, which may be embodied in various forms. Well-known functions or constructions are not described in detail to avoid obscuring the present disclosure in unnecessary detail. Therefore, specific structural and functional details disclosed herein are not to be interpreted as limiting, but merely as a basis for the claims and as a representative basis for teaching one skilled in the art to variously employ the present disclosure in virtually any appropriately detailed structure.
[008] The present invention relates to a stent. The stent includes a plurality of longitudinal segments wherein each longitudinal segments include a plurality of cells. The plurality of longitudinal segments defines a tubular structure. Each cell of the plurality of cells includes at least a first cell and a second cell. In an embodiment, each cell of the plurality of cells includes at least two of a proximal portion, a central portion and a distal portion. The proximal portion and the distal portion of a cell is formed of two angled struts defining a peak. The peaks are free and unbound. A proximal edge of the central portion of the second cell is placed on a proximal part of the distal portion of the first cell. The central portion of the first cells of each longitudinal segment is connected to either side of the first cells of adjacent longitudinal segments. Similarly, the central portion of the second cell of each longitudinal segment is connected to either side of second cells of the adjacent longitudinal segments. The distal portion of the first cell and the second cell is bent at a predefined angle a with respect to a longitudinal axis of the tubular structure.
BRIEF DESCRIPTION OF DRAWINGS
[009] The summary above, as well as the following detailed description of illustrative embodiments, is better understood when read in conjunction with the apportioned drawings. For the purpose of illustrating the present disclosure, exemplary constructions of the disclosure are shown in the drawings. However, the disclosure is not limited to specific methods and instrumentality disclosed herein. Moreover, those in the art will understand that the drawings are not to scale.
[0010] Fig. 1a depicts a superficial femoral artery and popliteal artery as examples where the teachings of the present disclosure are applicable.
[0011] Fig. 1b depicts stenosis/occlusions at multiple spots within the same artery, as examples where the teachings of the present disclosure are applicable.
[0012] Fig. 2 depicts a stent 100, in accordance with an embodiment of the present disclosure.
[0013] Fig. 3 depicts a cross sectional view of the stent 100, in accordance with an embodiment of the present disclosure.
[0014] Fig. 3a depicts a close-up view of one longitudinal segment 110, in accordance with an embodiment of the present disclosure.
DETAILED DESCRIPTION OF THE DRAWINGS
[0015] Prior to describing the disclosure in detail, definitions of certain words or phrases used throughout this patent document will be defined: the terms "include" and "comprise", as well as derivatives thereof, mean inclusion without limitation; the term "or" is inclusive, meaning and/or; the phrases "coupled with" and "associated therewith", as well as derivatives thereof, may mean to include, be included within, interconnect with, contain, be contained within, connect to or with, couple to or with, be communicable with, cooperate with, interleave, juxtapose, be proximate to, be bound to or with, have a property of, or the like. Definitions of certain words and phrases are provided throughout this patent document, and those of ordinary skill in the art will understand that such definitions apply in many, if not most, instances to prior as well as future uses of such defined words and phrases.
[0016] Reference throughout this specification to “one embodiment,” “an embodiment,” or similar language means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, appearances of the phrases “in one embodiment,” “in an embodiment,” and similar language throughout this specification may, but do not necessarily, all refer to the same embodiment, but mean “one or more but not all embodiments” unless expressly specified otherwise. The terms “including,” “comprising,” “having,” and variations thereof mean “including but not limited to” unless expressly specified otherwise. An enumerated listing of items does not imply that any or all of the items are mutually exclusive and/or mutually inclusive, unless expressly specified otherwise. The terms “a,” “an,” and “the” also refer to “one or more” unless expressly specified otherwise.
[0017] Although the operations of exemplary embodiments of the disclosed method may be described in a particular, sequential order for convenient presentation, it should be understood that the disclosed embodiments can encompass an order of operations other than the particular, sequential order disclosed. For example, operations described sequentially may in some cases be rearranged or performed concurrently. Further, descriptions and disclosures provided in association with one particular embodiment are not limited to that embodiment, and may be applied to any embodiment disclosed herein. Moreover, for the sake of simplicity, the attached figures may not show the various ways in which the disclosed system, method, and apparatus can be used in combination with other systems, methods, and apparatuses.
[0018] Furthermore, the described features, advantages, and characteristics of the embodiments may be combined in any suitable manner. One skilled in the relevant art will recognize that the embodiments may be practiced without one or more of the specific features or advantages of a particular embodiment. In other instances, additional features and advantages may be recognized in certain embodiments that may not be present in all embodiments. These features and advantages of the embodiments will become more fully apparent from the following description and apportioned claims, or may be learned by the practice of embodiments as set forth hereinafter.
[0019] The present disclosure discloses a stent. In an embodiment, the stent is a self-expanding stent. The stent may be manufactured of a biodegradable and/or biocompatible material. The stent has high radial strength as the stent can be implanted in arteries that are subjected to strong mechanical strain, involving bending and stretching, to treat complications such as stenosis, occlusions, etc. In an embodiment, the stent is implanted in peripheral arteries such as a superficial femoral artery, a popliteal artery etc.
[0020] In an embodiment, multiple stents can be implanted at multiple spots (or locations) in the same artery (as depicted in fig. 1b), each spot with stenosis/occlusion. In an exemplary embodiment, five to six stents each measuring 13 to 20 mm in length can be loaded on to a single delivery sheath and each of these stents can be implanted at corresponding occluded or stenosed spot in the artery via the single delivery sheath, as required. Alternatively, two to three stents each measuring 25 to 40 mm in length can be loaded to a single delivery sheath and each of these stents are implanted at occluded or stenosed spot in the artery via the single delivery sheath, as required. Thus, the dimensions of the stent along with the design features as detailed below, allow multi-spot stenting. That is, multiple stents at respective occluded or stenosed spots in a single artery which are in close proximity, can be deployed in one-go eliminating the need for a single long stent that covers the affected and unaffected portions of the artery. Multi-spot stenting further reduces material quantity as well as length of the stents inside a patient’s body. Reduction in the length of stent also minimizes problems associated with stent fractures.
[0021] The stent of the present disclosure includes multiple longitudinal segments. Each longitudinal segment includes a plurality of cells placed adjacent to each other. Each cell of the plurality of cells includes at least one free end that is bent outwards making an angle of 35-degrees wrt the longitudinal axis of the stent. The bent in the cells is incorporated to achieve an anti-jump design, ensuring minimal or no possibility of stent migration during the surgery and after implantation.
[0022] Now referring to the figures, Fig. 2 shows a stent 100 according to an embodiment. The stent 100 includes a body having a proximal end 100a and a distal end 100b. The stent 100 helps to treat conditions like stenosis or occlusion by providing structural support to narrowed or blocked arteries, promoting improved blood flow and preventing complications. The stent 100 has a central longitudinal axis that is substantially aligned with a central longitudinal axis of the artery when placed.
[0023] In the expanded configuration, the stent 100 defines a tubular structure including a lumen 101 through which the blood can flow. The lumen 101 extends from the proximal end 100a to the distal end 100b. The body of the stent 100 may have a uniform diameter or tapering diameter. In the latter case, as an example, the stent 100 may taper from the proximal end 100a to the distal end 100b as needed, basis the blood vessel where it is to be deployed.
[0024] The body of the stent 100 may be radially expandable and collapsible. That is, the body of the stent 100 can be collapsed to a form a narrow profile configuration of the stent 100 for delivery to a target site such as femoral arteries. When placed in the target site, the stent 100 can be expanded from the narrow profile configuration to a wide profile configuration.
[0025] The stent 100 includes a plurality of longitudinal segments that define the tubular structure. That is, the longitudinal segments are placed one after the other so as to form the tubular structure. In an embodiment, the stent 100 includes four longitudinal segments, a first longitudinal segment 110 (hereinafter referred as first longitudinal segment 110), a second longitudinal segment 120 (hereinafter referred as second longitudinal segment 120), a third longitudinal segment 130 (hereinafter referred as third longitudinal segment 130), and a fourth longitudinal segment 140 (hereinafter referred as fourth longitudinal segment 140). Depending upon the diameter of the annulus where the stent 100 is to be deployed, the number of longitudinal segments may be increased or decreased.
[0026] The stent 100 may have a height and a diameter ranging from 13 mm to 40 mm and 4 mm to 8 mm, respectively. In an exemplary embodiment, the height and the diameter of the stent 100 is 6 mm and 15 mm, respectively. The stent 100 may be made of a self-expanding material such as, without limitation, nitinol, cobalt-chromium, stainless steel, etc. In an exemplary embodiment, the stent 100 is made of nitinol. Any other biodegradable and/or biocompatible material can also be used to manufacture the stent 100.
[0027] Each longitudinal segment include a plurality of cells. The plurality of cells includes at least a first cell and a second cell (as shown in Fig. 3). In an exemplary implementation, the first longitudinal segment 110 includes three cells, namely, a first cell 111, a second cell 113 and a third cell 115. Similarly, the second longitudinal segment 120 includes three cells, namely, a first cell 121, a second cell 123 and a third cell 125. The third longitudinal segment 130 includes three cells, namely, a first cell 131, a second cell 133 and a third cell 135. The fourth longitudinal segment 140 also includes three cells, namely a first cell 141, a second cell 143 and a third cell 145.
[0028] Each cell of the plurality of cells has a pre-defined shape. In an exemplary embodiment, each cell of the plurality of cells is leaf shaped. The advantages of leaf shaped cells include smooth expansion of the stent 100, uniform distribution of radial force, ease in loading the stent 100 on a delivery system, deployment or recapturing of the stent 100, etc. While the cells are depicted to be leaf-shaped, the shape of the cells can be without limitation oval, obovate, cup, diamond, etc. While the description below elaborates the teachings of the present disclosure using only leaf-shaped cells, it is possible that different longitudinal segments may include cells of different shapes or a single longitudinal segment may include cells of varying shapes and sizes.
[0029] Further, a cell may be formed of two or more portions. For example, a cell formed of three portions include a proximal portion (P), a central portion (C) and a distal portion (D) while a cell formed of two portions include a central portion (C) and a distal portion (D). In an embodiment, the first cell 111 includes all the three portions and resembles a complete leaf while the second cell 113 and third cell 115 include only central portions (C) and distal portions (D) and resemble a leaf segment. Due to this, the second cell 113 and the third cell 115 of the first longitudinal segment 110 may be of shorter heights compared to the first cell 111. The first cell 111 may have a height and width ranging from 6 mm to 20 mm and 3 mm and 7 mm. In an exemplary embodiment, the first cell 111 has a height and width of 9 mm and 4.2 mm. In an embodiment, the height of the second cell 113 and third cell 115 is 60-70% of the height of the first cell 111. The second cell 113 and the third cell 115 may have a height and width ranging from 3.5mm to 14 mm and 3 mm and 7 mm, respectively. In an exemplary embodiment, the height and width of the second cell 113 and third cell 115 equals to 5.86 mm and 4.2 mm, respectively.
[0030] The central portion (C) of a cell (e.g., a first cell, a second cell or a third cell) is defined by two struts spaced apart from each other defining a bulge of the respective cell. Each of the proximal portion (P) and the distal portion (D) of a cell (e.g., a first cell, a second cell or a third cell) is formed of two angled struts defining a peak as shown in Fig. 3a. In an embodiment, the angled struts define a V-shape. The angle ß between the V-shaped struts may range between 50 degrees to 90 degrees. In an exemplary embodiment, the angle ß is 65 degrees. For example, struts (111e, 121e, 131e, 141e) and (111f, 121f, 131f, 141f) of the proximal portion (P) of the first cell (111, 121, 131, 141) define a peak (S1). Similarly, struts (111a, 121a, 131a, 141a) and (111b, 121b, 131b, 141b) of the distal portion (D) of the first cell (111, 121, 131, 141) define a peak (S2). The struts (113a, 123a, 133a, 143a) and (113b, 123b, 133b, 143b) of the distal portion (D) of the second cell (113, 123, 133, 143) define a peak (S3). The struts (115a, 125a, 135a, 145a) and (115b, 125b, 135b, 145b) of the distal portion (D) of the third cell (115, 125, 135, 145) define a peak (S4). The struts 111a-b, 111e-f, 113a-b, 115a-b, 121a-b, 123a-b, 125a-b, 131a-b, 133a-b, 135a-b, 141a-b, 143a-b, 145a-b may have a length ranging from 0.45 mm to 1 mm. In an exemplary embodiment, the struts 111a-b, 111e-f, 113a-b, 115a-b, 121a-b, 123a-b, 125a-b, 131a-b, 133a-b, 135a-b, 141a-b, 143a-b, 145a-b include a length of 0.8 mm. In an embodiment, all the peaks S1, S2, S3, S4 are unbound to a neighboring strut or cell. That is, the peaks S1, S2, S3, S4 are free and not coupled to any neighboring strut or cell.
[0031] The proximal edge of central portion (C) of the second cell 113 is placed on the proximal part of distal portion (D) of the first cell 111 (shown in fig. 3a). The proximal edge of central portion (C) of the third cell 115 is placed on the proximal part of distal portion (D) of the second cell 113 as shown in the depicted embodiment (shown in fig. 3a).
[0032] In an embodiment, the design of the second, third and fourth longitudinal segments 120, 130 and 140 are similar to the design of the first longitudinal segment 110. For example, the proximal portion (P), central portion (C) and the distal portion (D) of cells of the second longitudinal segment 120, the third longitudinal segment 130 and the fourth longitudinal segment 140 are similar to the first longitudinal segment 110. Therefore, the details of the first longitudinal segment 110 are applicable to the second, third and fourth longitudinal segments 120, 130 and 140 and not repeated for the sake of brevity.
[0033] Alternately, it is possible that the dimensions of the first, second, third and fourth longitudinal segments 110, 120, 130 and 140 may be same or may differ from each other. For example, the first longitudinal segment 110 and the third longitudinal segments 130 may be narrower compared to the second longitudinal segment 120 and fourth longitudinal segment 140. The dimensions include the length and diameter of the cells of a longitudinal segment. Other variations of dimensions of the longitudinal segments are within the teachings of the present disclosure.
[0034] In an embodiment, the first cells 111, 121, 131, 141 form a first row of the stent 100. Similarly, the second cells 113, 123, 133, 143 form a second row of the stent 100. Similarly, the third cells 115, 125, 135, 145 form a third row of the stent 100.
[0035] In an embodiment, each cell in the first row is connected to two adjacent cells in the first row and one adjacent cell in the second row. For example, the first cell 111 of the first longitudinal segment 110 is connected to the first cell 121 of the second longitudinal segment 120 and the first cell 141 of the fourth longitudinal segment 140. The first cell 111 of the first longitudinal segment 110 is also connected to the second cell 113 of the first longitudinal segment 110.
[0036] In an exemplary embodiment, the central portion (C) of the first cell 111 of the first longitudinal segment 110 is connected to the central portion (C) of first cell 121 of the second longitudinal segment 120 on one side and the central portion (C) of first cell 141 of the fourth longitudinal segment 140 on the other side. The proximal part of the distal portion (D) of the first cell 111 is connected to the proximal edge of the central portion (C) of the second cell 113. Likewise, all the first cells 111, 121, 131, 141 of the first row are connected to each other and form the first row R1.
[0037] In an exemplary embodiment, the proximal portion (P) including the peak S1 of the first cell (111, 121, 131, or 141) and the distal portion (D) including the peak S2 of the first cell (111, 121, 131, or 141) are bent outwards (that is, away from the lumen 101 as depicted in Fig. 2) at a predefined angle a ranging from 0 degrees to 45-degrees wrt the longitudinal axis of the tubular structure. The angle a may vary from peak to peak and cell to cell. The bends of the distal portions (D) along with peak S2 of the cells is possible due to the peaks being free and unbound. The bend helps to achieve an anti-jump design, ensuring minimal or no possibility of migration of stent 100 during the surgery and after implantation.
[0038] In an embodiment, each cell in the second row is connected to two adjacent cells in the second row, one cell in the first row and one cell in the third row. For example, the second cell 113 of the first longitudinal segment 110 is connected to the second cell 123 of the second longitudinal segment 120 and the second cell 143 of the fourth longitudinal segment 140. The second cell 113 of the first longitudinal segment 110 is also connected to the first cell 111 and the third cell 115 of the first longitudinal segment 110.
[0039] In an exemplary embodiment, the central portion (C) of the second cell 113 of the first longitudinal segment 110 is connected to the central portion (C) of second cell 123 of the second longitudinal segment 120 on one side and the central portion (C) of second cell 143 of the fourth longitudinal segment 140 on the other side. Likewise, all the second cells 113, 123, 133, 143 of the second row are connected to each other and form the second row R2.
[0040] Further, the proximal edge of the central portion (C) of the second cell 113 of the first longitudinal segment 110 is placed on the proximal part of the distal portion (D) of the first cell 111 of the first longitudinal segment 110. Likewise, the second cells 123, 133, 143 of the second row are placed on the first cells 121, 131, 141 respectively of the first row. The proximal part of the distal portion (D) of the second cell 113 is connected to the proximal edge of the central portion (C) of the third cell 115.
[0041] In an exemplary embodiment, the distal portion (D) including the peak S3 of the second cells 113, 123, 133, 133 are bent outwards (that is, away from the lumen 101as depicted in Fig. 2) at a predefined angle a ranging from 0 degrees to 45 degrees wrt the longitudinal axis of the tubular structure. The angle a may vary from peak to peak and cell to cell. The bends of the distal portions (D) along with peak S3 of the cells is possible due to the peaks being free and unbound. The bent helps to achieve an anti-jump design, ensuring minimal or no possibility of migration of stent 100 during the surgery and after implantation.
[0042] In an embodiment, each cell in the third row is connected to the two adjacent cells in the third row and one adjacent cell in the second row. For example, the third cell 115 of the first longitudinal segment 110 is connected to the third cell 125 of the second longitudinal segment 120 and the third cell 145 of the fourth longitudinal segment 140. The third cell 115 of the first longitudinal segment 110 is also connected to second cell 113 of the first longitudinal segment 110.
[0043] In an exemplary embodiment, the central portion (C) of the third cell 115 of the first longitudinal segment 110 is connected to the central portion (C) of third cell 125 of the second longitudinal segment 120 on one side and the central portion (C) of third cell 145 of the fourth longitudinal segment 140 on the other side. Likewise, all the cells 115, 125, 135, 145 of the third row are connected to each other and form the third row R3. Further, the proximal edge of the central portion (C) of the third cell 115 of the first longitudinal segment 110 is placed on the proximal part of distal portion (D) of the second cell 113 of the first longitudinal segment 110. Likewise, the third cells 125, 135, 145 of the third row are placed on the second cells 123, 133, 143 respectively of the second row.
[0044] In an exemplary embodiment, the distal portion (D) including the peak S4 of the third cells 115, 125, 135, 145 are bent outwards (that is, away from the lumen 101 as depicted in Fig. 2) at a predefined angle a ranging from 0 degrees to 45-degrees wrt the longitudinal axis of the tubular structure. The angle a may vary from peak to peak and cell to cell. The bends of the distal portions (D) along with peak S4 of the cells is possible due to the peaks being free and unbound. The bent helps to achieve an anti-jump design, ensuring minimal or no possibility of migration of stent 100 during the surgery and after implantation.
[0045] Further, a strut (113c, 123c, 133c or 143c) on one side of the central portion (C) of the second cell (113, 123, 133 or 143) forms an angle ? with the adjacent strut (111a, 121a, 131a or 141a) on a side of the distal portion (D) of the first cell (111, 121, 131 or 141), respectively (as shown in Fig. 2). Similarly, a strut (113d, 123d, 133d or 143d) on the other side of the central portion (C) of the second cell (113, 123, 133 or 143) forms an angle ? with the adjacent strut (111b, 121b, 131b or 141b) on the other of the distal portion (D) of the first cell (111, 121, 131 or 141), respectively (as shown in Fig. 2). In an embodiment, the angle ? ranges from 30 deg to 90 deg. In an exemplary embodiment, the angle ? is 70 deg. Likewise, a strut (115c, 125c, 135c or 145c) on one side of the central portion (C) of the third cell (115, 125, 135 or 145) forms an angle ? with the adjacent strut (113a, 123a, 133a or 143a) on a side of the distal portion (D) of the second cell (113, 123, 133 or 143) (as shown in Fig. 2). Similarly, a strut (115d, 125d, 135d or 145d) on the other side of the central portion (C) of the third cell (115, 125, 135 or 145) forms an angle ? with the adjacent strut (113b, 123b, 133b or 143b) on the other of the distal portion (D) of the second cell (113, 123, 133 or 143) (as shown in Fig. 2). In an embodiment, the angle ? ranges from 30 deg to 90 deg. In an exemplary embodiment, the angle ? is 70 deg.
[0046] The aforesaid stent 100 may be manufactured by laser cutting a tube and thereafter, subjecting the cut tube to heat treatment with a help of a mold to get the required bends and shape. Other process, such as, sand blasting, electro polishing, etc. has been done to get the finished product i.e. the stent 100.The stent 100, thus obtained has a unitary structure.
[0047] While the above stent 100 is described having four longitudinal segments and three cells in each segment, it is possible to vary both, the number of segments and the number of cells depending upon application.
[0048] The scope of the invention is only limited by the appended patent claims. More generally, those skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are meant to be exemplary and that the actual parameters, dimensions, materials, and/or configurations will depend upon the specific application or applications for which the teachings of the present invention is/are used. , Claims:WE CLAIM:
1. A stent (100), comprising:
a. a plurality of longitudinal segments defining a tubular structure; and
b. a plurality of cells in each longitudinal segment including at least a first cell and a second cell, each cell of the plurality of cells includes at least two of a proximal portion (P), a central portion (C) and a distal portion (D);
wherein each of the proximal portion (P) and the distal portion (D) is formed of two angled struts defining a peak (S1, S2, S3, S4);
wherein the peak (S1, S2, S3, S4) is free and unbound;
wherein a proximal edge of the central portion (C) of the second cell (113) is placed on a proximal part of the distal portion (D) of the first cell (111);
wherein the central portion (C) of the first cells (111, 121, 131, 141) of the longitudinal segment (110, 120, 130, 140) is connected to either sides of first cells of adjacent longitudinal segments;
wherein the central portion (C) of the second cell (113, 123, 133, 143) of the longitudinal segment (110, 120, 130, 140) is connected to either sides of second cells of the adjacent longitudinal segments ; and
wherein the distal portion (D) of the first cell (111, 121, 131, 141) and the second cell (113, 123, 133, 143) is bent at a predefined angle a with respect to a longitudinal axis of the tubular structure.
2. The stent (100) as claimed in claim 1, wherein the plurality of longitudinal segments includes a first segment (110), a second segment (120), a third segment (130), a fourth segment (140).
3. The stent (100) as claimed in claim 1, wherein in addition to the first cell (111, 121, 131, 141) and the second cell (113, 123, 133, 143), each longitudinal segment includes a third cell (115, 125, 135, 145).
4. The stent (100) as claimed in claim 3, wherein the plurality of longitudinal segments of the tubular structure defines three rows of cells.
5. The stent (100) as claimed in claim 1, wherein the shape of the cell includes leaf shape, oval, obovate, cup, diamond, etc. or combinations thereof.
6. The stent (100) as claimed in claim 1, wherein the predefined angle a ranges from 0 degrees to 45 degrees.
7. The stent (100) as claimed in claim 1, wherein the angled struts define peaks having an angle ß ranging from 50 degrees to 90 degrees.
8. The stent (100) as claimed in claim 1, wherein the longitudinal segments are made from a biodegradable material or a biocompatible material or a self-expanding material such as nitinol, cobalt-chromium, stainless steel, etc.
9. The stent (100) as claimed in claim 1, wherein the stent 100 is a unitary structure made via laser cutting and heat setting techniques.